The European Medicines Agency granted priority medicine designation to ANX007 for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Annexon Biosciences.
“PRIME designation for ANX007 is an important and exciting step for the entire field of ophthalmology retina specialists,” Douglas Love, president and CEO of Annexon, told Healio. “The designation represents external regulatory validation of both the unmet medical need for geographic atrophy that the field well recognizes and, more specifically, the strength